Laking GR[au] - Search Results

Year	Number of Results
1978	1
2002	4
2003	2
2006	1
2010	1
2015	1
2017	1
2019	1
2020	1
2023	0

1

Imaging vascular physiology to monitor cancer treatment.

Laking GR, West C, Buckley DL, Matthews J, Price PM. Laking GR, et al. Crit Rev Oncol Hematol. 2006 May;58(2):95-113. doi: 10.1016/j.critrevonc.2005.10.006. Epub 2006 Jan 4. Crit Rev Oncol Hematol. 2006. PMID: 16387510 Review.

2

Assessment of the technology for functional imaging in cancer.

Laking GR, Price PM, Sculpher MJ. Laking GR, et al. Eur J Cancer. 2002 Nov;38(16):2194-9. doi: 10.1016/s0959-8049(02)00385-4. Eur J Cancer. 2002. PMID: 12387844 Review.

3

Positron emission tomographic imaging of angiogenesis and vascular function.

Laking GR, Price PM. Laking GR, et al. Br J Radiol. 2003;76 Spec No 1:S50-9. doi: 10.1259/bjr/30399077. Br J Radiol. 2003. PMID: 15456714 Review.

4

Human Exposure to Radioactivity From Tobacco Smoke: Systematic Review.

Laking GR. Laking GR. Nicotine Tob Res. 2019 Aug 19;21(9):1172-1180. doi: 10.1093/ntr/nty111. Nicotine Tob Res. 2019. PMID: 30060241

5

Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.

Beatty PA, Laking GR. Beatty PA, et al. Among authors: laking gr. J Oncol Pract. 2015 May;11(3):249-51. doi: 10.1200/JOP.2014.000083. Epub 2015 Mar 31. J Oncol Pract. 2015. PMID: 25829524 No abstract available.

6

Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.

McKeage MJ, Tin Tin S, Khwaounjoo P, Sheath K, Dixon-McIver A, Ng D, Sullivan R, Cameron L, Shepherd P, Laking GR, Kingston N, Strauss M, Lewis C, Elwood M, Love DR. McKeage MJ, et al. Among authors: laking gr. Intern Med J. 2020 Jun;50(6):716-725. doi: 10.1111/imj.14435. Intern Med J. 2020. PMID: 31318119

7

Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?

Helsby NA, Lo WY, Thompson P, Laking GR. Helsby NA, et al. Among authors: laking gr. Cancer Chemother Pharmacol. 2010 Jul;66(2):405-7. doi: 10.1007/s00280-010-1277-1. Epub 2010 Feb 17. Cancer Chemother Pharmacol. 2010. PMID: 20162308

8

On the development of rational standards for nuclear response evaluation.

Laking GR, Price PM. Laking GR, et al. Q J Nucl Med. 2003 Mar;47(1):3-7. Q J Nucl Med. 2003. PMID: 12714948 Free article. Review.

9

FDG-PET for response assessment: answers in search of questions.

Laking GR, Price PM. Laking GR, et al. Ann Oncol. 2002 Mar;13(3):345-7. doi: 10.1093/annonc/mdf144. Ann Oncol. 2002. PMID: 11996462 Free article. No abstract available.

10

Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test.

Shepherd P, Sheath KL, Tin ST, Khwaounjoo P, Aye PS, Li A, Laking GR, Kingston NJ, Lewis CA, Mark Elwood J, Love DR, McKeage MJ. Shepherd P, et al. Among authors: laking gr. Oncotarget. 2017 Sep 16;8(60):101437-101451. doi: 10.18632/oncotarget.21023. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254176 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results